Interim efficacy analysis for Riquent slated for December
This article was originally published in Scrip
Executive Summary
La Jolla Pharmaceutical has a significant milestone at the end of the year – the first of two interim efficacy analyses of its ongoing, large-scale Phase III trial of its lupus erythematosus treatment, Riquent (abetimus sodium), CEO Dr Deirdre Gillespie told investors at the Cannacord Adams Global Growth Conference. Final data are now anticipated by about October 2009.